Search research articles
Contact Us
Filters
Showing results (31-40 of 186) with videos related to
Page
of 19
Sort By:
Rheumatology (Oxford, England)
|
July 9, 2022
Adverse events of treatment with rituximab in patients with myositis
Sergio Gilaberte, Joana Rua, David Isenberg
Rheumatology (Oxford, England)
|
March 19, 2010
Working through the recession
Lynne Shand, Sara Cortes, David Isenberg
Lupus
|
March 29, 2008
Introduction to a systemic lupus erythematosus - biomarkers meeting held at University College London on 23rd and 24th February 2007
David Isenberg, Michael Ehrenstein, Anisur Rahman
Lancet (London, England)
|
August 27, 2013
Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment
Grainne Murphy, Larissa Lisnevskaia, David Isenberg
Lancet (London, England)
|
June 3, 2014
Systemic lupus erythematosus
Larissa Lisnevskaia, Grainne Murphy, David Isenberg
Rheumatology (Oxford, England)
|
May 4, 2021
IgG vs IgG + IgM anti-double stranded DNA measurement: a comparative report for clinical practice
Rym Abida, Emily Apsley, David Isenberg
Clinical Rheumatology
|
December 24, 2024
Identification of patients with ANA-negative and double-stranded DNA positive: what is the significance in daily rheumatology practice?
Güllü Sandal Uzun, Emily Apsley, David Isenberg
Rheumatology (Oxford, England)
|
October 25, 2014
Biologic treatment in Sjögren's syndrome
Pablo Ruiz Sada, David Isenberg, Coziana Ciurtin
Lupus Science & Medicine
|
March 1, 2017
The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness
Borja Gracia-Tello, Amara Ezeonyeji, David Isenberg
Expert Opinion on Drug Safety
|
May 10, 2016
The safety of pharmacological treatment options for lupus nephritis
Alba Velo-García, Eleana Ntatsaki, David Isenberg
Page
of 19
Search research articles
Search
Showing results (31-40 of 186) with videos related to
Sort By:
Page
of 19
Rheumatology (Oxford, England)
|
July 9, 2022
Adverse events of treatment with rituximab in patients with myositis
Sergio Gilaberte, Joana Rua, David Isenberg
Rheumatology (Oxford, England)
|
March 19, 2010
Working through the recession
Lynne Shand, Sara Cortes, David Isenberg
Lupus
|
March 29, 2008
Introduction to a systemic lupus erythematosus - biomarkers meeting held at University College London on 23rd and 24th February 2007
David Isenberg, Michael Ehrenstein, Anisur Rahman
Lancet (London, England)
|
August 27, 2013
Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment
Grainne Murphy, Larissa Lisnevskaia, David Isenberg
Lancet (London, England)
|
June 3, 2014
Systemic lupus erythematosus
Larissa Lisnevskaia, Grainne Murphy, David Isenberg
Rheumatology (Oxford, England)
|
May 4, 2021
IgG vs IgG + IgM anti-double stranded DNA measurement: a comparative report for clinical practice
Rym Abida, Emily Apsley, David Isenberg
Clinical Rheumatology
|
December 24, 2024
Identification of patients with ANA-negative and double-stranded DNA positive: what is the significance in daily rheumatology practice?
Güllü Sandal Uzun, Emily Apsley, David Isenberg
Rheumatology (Oxford, England)
|
October 25, 2014
Biologic treatment in Sjögren's syndrome
Pablo Ruiz Sada, David Isenberg, Coziana Ciurtin
Lupus Science & Medicine
|
March 1, 2017
The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness
Borja Gracia-Tello, Amara Ezeonyeji, David Isenberg
Expert Opinion on Drug Safety
|
May 10, 2016
The safety of pharmacological treatment options for lupus nephritis
Alba Velo-García, Eleana Ntatsaki, David Isenberg
Page
of 19